[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,900,274
  • Shares Outstanding, K 254,008
  • Annual Sales, $ 2,320 M
  • Annual Income, $ 782,570 K
  • EBIT $ 872 M
  • EBITDA $ 901 M
  • 60-Month Beta 0.42
  • Price/Sales 5.02
  • Price/Cash Flow 15.16
  • Price/Book 5.69

Options Overview Details

View History
  • Implied Volatility 47.65% (+2.98%)
  • Historical Volatility 29.32%
  • IV Percentile 86%
  • IV Rank 47.95%
  • IV High 71.05% on 10/17/25
  • IV Low 26.11% on 06/06/25
  • Expected Move (DTE 22) 1.91 (4.11%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 69
  • Volume Avg (30-Day) 637
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 25,776
  • Open Int (30-Day) 25,389
  • Expected Range 44.67 to 48.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.68
  • Number of Estimates 6
  • High Estimate $0.76
  • Low Estimate $0.60
  • Prior Year $0.53
  • Growth Rate Est. (year over year) +28.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.84 +14.25%
on 03/24/26
47.47 -1.72%
on 04/22/26
+5.24 (+12.67%)
since 03/23/26
3-Month
39.71 +17.49%
on 03/02/26
47.47 -1.72%
on 04/22/26
+2.38 (+5.39%)
since 01/23/26
52-Week
33.76 +38.22%
on 10/20/25
49.62 -5.98%
on 06/23/25
+9.88 (+26.85%)
since 04/23/25

Most Recent Stories

More News
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 46.48 (-0.79%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

- Presentations to be webcast on www.exelixis.com -

EXEL : 46.48 (-0.79%)
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion

EXEL : 46.48 (-0.79%)
Exelixis: Q4 Earnings Snapshot

Exelixis: Q4 Earnings Snapshot

EXEL : 46.48 (-0.79%)
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – ...

EXEL : 46.48 (-0.79%)
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results...

EXEL : 46.48 (-0.79%)
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 46.48 (-0.79%)
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal...

EXEL : 46.48 (-0.79%)
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy –

NTRA : 195.26 (-6.03%)
EXEL : 46.48 (-0.79%)
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

– Presentation to be webcast on www.exelixis.com –

EXEL : 46.48 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 49.39
2nd Resistance Point 48.43
1st Resistance Point 47.64
Last Price 46.48
1st Support Level 45.89
2nd Support Level 44.93
3rd Support Level 44.14

See More

52-Week High 49.62
Last Price 46.48
Fibonacci 61.8% 43.56
Fibonacci 50% 41.69
Fibonacci 38.2% 39.82
52-Week Low 33.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.